Tolvaptan for polycystic kidney, autosomal recessive

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 4 Mar 2021: Trial registered, NCT04782258
  2. 23 Jan 2023: Trial started, NCT04782258

The trials

NCT04782258: A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)

State
Under way
Phase
Phase 3
People
20 planned
Started
23 Jan 2023
Primary completion
28 Dec 2028
Arms
Tolvaptan Suspension, Tolvaptan Tablets
Results
None posted
  1. 4 Mar 2021: Trial registered
  2. 23 Jan 2023: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as Jinarc, Jynarque, Samsca, Tolvaptan Suspension, Tolvaptan Tablets.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.